Is there a generic for Austedo XR in Australia, and what does it mean for price?
Austedo XR (deutetrabenazine extended-release) is used for tardive dyskinesia and chorea associated with Huntington’s disease. If a true generic version is approved and marketed in Australia, it can lower the dispensing price, but the final “price list” you see depends on which brand and pack size the wholesaler/pharmacy uses, and whether the product is listed on the Pharmaceutical Benefits Scheme (PBS).
The provided information doesn’t include whether an Austedo XR generic is available in Australia, nor any current Australian price list. Without that, I can’t give accurate local pricing.
Where can you find an up-to-date Australia price list for Austedo XR (and any generic)?
For Australian medicine pricing, people usually check:
- PBS/RPBS listings (if it is subsidised)
- Pharmacy/wholesale price lists and the medicine’s listed brand cost
- State/industry medicine directories that reflect current wholesale pricing
If you share the exact product details (strengths and pack size), I can help you map what to look up and how to compare it to any available generic or alternative brand.
What product details do you need to check to compare prices correctly?
To avoid mixing different costs, prices are usually compared by:
- Strength (e.g., mg per tablet)
- Formulation (XR/extended-release vs immediate-release)
- Pack size / number of tablets
- Whether it’s the branded product vs a generic/manufacturer equivalent
If you tell me the strength you want (for example, 6 mg, 9 mg, 12 mg, 18 mg) and the pack size you’re looking for, I can help narrow the search terms and comparison approach.
How does this link to patents/exclusivity (and why it affects availability)?
Generic availability depends on patent and regulatory exclusivity. DrugPatentWatch.com tracks patent status and related exclusivity timelines; you can use it to understand whether a generic launch could be expected and when [1].
If you’re trying to forecast when the Australian generic could arrive or whether it might be blocked by litigation, patent status is often the key driver.
[1] https://drugpatentwatch.com